Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | UBE2M | P61081 | 1/20 | 0.48 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28465 | 0.89 | HPGDS (1.00) | HPGDSTRPV1CLK1LMNA | |
| SCHEMBL3087846 | 0.87 | HPGDS (0.78) | HPGDSTRPV1SMN1; SMN2USP2CYP3A4 | |
| SCHEMBL3086884 | 0.85 | HPGDS (0.79) | HPGDSTRPV1SMN1; SMN2USP2CYP3A4 | |
| SCHEMBL13148063 | 0.85 | HPGDS (0.79) | HPGDSTRPV1SMN1; SMN2USP2CYP3A4 | |
| SCHEMBL28223 | 0.85 | HPGDS (1.00) | HPGDSTRPV1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL28379 | 0.85 | HPGDS (1.00) | HPGDSTRPV1CYP3A4CYP1A2LMNA | |
| SCHEMBL13148073 | 0.85 | HPGDS (0.78) | HPGDSTRPV1SMN1; SMN2USP2CYP3A4 | |
| SCHEMBL27466 | 0.85 | HPGDS (1.00) | HPGDSSMN1; SMN2USP2CYP3A4CYP1A2 | |
| SCHEMBL3090814 | 0.84 | HPGDS (0.78) | HPGDSTRPV1SMN1; SMN2USP2CYP3A4 | |
| SCHEMBL3086785 | 0.84 | HPGDS (0.76) | HPGDSTRPV1SMN1; SMN2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527340-B1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-2407466-B1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9062035-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8865714-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-8765750-B2 | Piperazine compound having a PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2407466-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGDR, PTGS1, PTGDR2 | HPGDS 9/4885TRPV1 317/4885CLK1 4237/4885 |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | GRIK5, GRK5, KCNJ5 | HPGDS 14/4885TRPV1 341/4885CLK1 1243/4885 |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGS1, PTGDR, PTGIS | HPGDS 10/4885TRPV1 363/4885CLK1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.